Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 18/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.46 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15158795 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL19341925 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL19351795 | 0.87 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19351949 | 0.87 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL16657558 | 0.87 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19351793 | 0.87 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19351945 | 0.87 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21321912 | 0.86 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18798686 | 0.86 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLAEPHX2 | |
| SCHEMBL15762838 | 0.84 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
| US-20170258932-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885NAALAD2 50/4885RIMKLA 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.